Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1

Jie Fan, Margaret M. Wojnar, Matthew Theodorakis, Charles H. Lang

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

The purpose of the present study was to determine whether interleukin (IL)-1 would alter the insulin-like growth factor (IGF) system in rats and whether this change was mediated by glucocorticoids. The IGF-I concentration was decreased in plasma (32%), liver (35%), skeletal muscle (40-50% depending on fiber type), pituitary (36%), and brain (52%), and increased in kidney (73%) 6 h after intravenous injection of IL-1β. IL-1β also decreased IGF-I mRNA levels in liver and muscle and increased expression in kidney. These changes were associated with a >2.5-fold elevation in plasma corticosterone levels. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 prevented the IL-1β-induced decrease in plasma and liver IGF-I concentration and the reduction in hepatic IGF-I mRNA expression. In contrast, RU-486 did not significantly attenuate the fall in IGF-I content in skeletal muscle, heart, brain, or pituitary or the increase in IGF-I observed in kidney after IL-1β. Furthermore, pretreatment with RU-486 did not completely prevent the IL-1β-induced decrease in IGF-I mRNA in skeletal muscle. The concentration of both IGF-binding protein (BP)-1 and BP-2 was increased in plasma, liver, and muscle in response to IL-1β, and these changes were also not prevented by RU-486. These results indicate that the inflammatory cytokine IL-1β is capable of influencing multiple components of the IGF system. Whereas the enhanced endogenous production of glucocorticoids appears to mediate the IL-1β-induced decrease in IGF-I synthesis in liver, the changes in IGF-I content observed in other tissues and the increase in IGFBP-1 and IGFBP-2 appear to be largely glucocorticoid independent.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume270
Issue number3 39-3
StatePublished - Dec 1 1996

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor I
Interleukin-1
Messenger RNA
Peptides
Mifepristone
Liver
Glucocorticoids
Skeletal Muscle
Somatomedins
Kidney
Insulin-Like Growth Factor Binding Protein 2
Muscles
Glucocorticoid Receptors
Brain
Corticosterone
Protein Binding
Intravenous Injections
Carrier Proteins
Cytokines

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)

Cite this

@article{90ab1cc876364d41b16087514bf36727,
title = "Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1",
abstract = "The purpose of the present study was to determine whether interleukin (IL)-1 would alter the insulin-like growth factor (IGF) system in rats and whether this change was mediated by glucocorticoids. The IGF-I concentration was decreased in plasma (32{\%}), liver (35{\%}), skeletal muscle (40-50{\%} depending on fiber type), pituitary (36{\%}), and brain (52{\%}), and increased in kidney (73{\%}) 6 h after intravenous injection of IL-1β. IL-1β also decreased IGF-I mRNA levels in liver and muscle and increased expression in kidney. These changes were associated with a >2.5-fold elevation in plasma corticosterone levels. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 prevented the IL-1β-induced decrease in plasma and liver IGF-I concentration and the reduction in hepatic IGF-I mRNA expression. In contrast, RU-486 did not significantly attenuate the fall in IGF-I content in skeletal muscle, heart, brain, or pituitary or the increase in IGF-I observed in kidney after IL-1β. Furthermore, pretreatment with RU-486 did not completely prevent the IL-1β-induced decrease in IGF-I mRNA in skeletal muscle. The concentration of both IGF-binding protein (BP)-1 and BP-2 was increased in plasma, liver, and muscle in response to IL-1β, and these changes were also not prevented by RU-486. These results indicate that the inflammatory cytokine IL-1β is capable of influencing multiple components of the IGF system. Whereas the enhanced endogenous production of glucocorticoids appears to mediate the IL-1β-induced decrease in IGF-I synthesis in liver, the changes in IGF-I content observed in other tissues and the increase in IGFBP-1 and IGFBP-2 appear to be largely glucocorticoid independent.",
author = "Jie Fan and Wojnar, {Margaret M.} and Matthew Theodorakis and Lang, {Charles H.}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "270",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "3 39-3",

}

TY - JOUR

T1 - Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1

AU - Fan, Jie

AU - Wojnar, Margaret M.

AU - Theodorakis, Matthew

AU - Lang, Charles H.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The purpose of the present study was to determine whether interleukin (IL)-1 would alter the insulin-like growth factor (IGF) system in rats and whether this change was mediated by glucocorticoids. The IGF-I concentration was decreased in plasma (32%), liver (35%), skeletal muscle (40-50% depending on fiber type), pituitary (36%), and brain (52%), and increased in kidney (73%) 6 h after intravenous injection of IL-1β. IL-1β also decreased IGF-I mRNA levels in liver and muscle and increased expression in kidney. These changes were associated with a >2.5-fold elevation in plasma corticosterone levels. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 prevented the IL-1β-induced decrease in plasma and liver IGF-I concentration and the reduction in hepatic IGF-I mRNA expression. In contrast, RU-486 did not significantly attenuate the fall in IGF-I content in skeletal muscle, heart, brain, or pituitary or the increase in IGF-I observed in kidney after IL-1β. Furthermore, pretreatment with RU-486 did not completely prevent the IL-1β-induced decrease in IGF-I mRNA in skeletal muscle. The concentration of both IGF-binding protein (BP)-1 and BP-2 was increased in plasma, liver, and muscle in response to IL-1β, and these changes were also not prevented by RU-486. These results indicate that the inflammatory cytokine IL-1β is capable of influencing multiple components of the IGF system. Whereas the enhanced endogenous production of glucocorticoids appears to mediate the IL-1β-induced decrease in IGF-I synthesis in liver, the changes in IGF-I content observed in other tissues and the increase in IGFBP-1 and IGFBP-2 appear to be largely glucocorticoid independent.

AB - The purpose of the present study was to determine whether interleukin (IL)-1 would alter the insulin-like growth factor (IGF) system in rats and whether this change was mediated by glucocorticoids. The IGF-I concentration was decreased in plasma (32%), liver (35%), skeletal muscle (40-50% depending on fiber type), pituitary (36%), and brain (52%), and increased in kidney (73%) 6 h after intravenous injection of IL-1β. IL-1β also decreased IGF-I mRNA levels in liver and muscle and increased expression in kidney. These changes were associated with a >2.5-fold elevation in plasma corticosterone levels. Pretreatment of rats with the glucocorticoid receptor antagonist RU-486 prevented the IL-1β-induced decrease in plasma and liver IGF-I concentration and the reduction in hepatic IGF-I mRNA expression. In contrast, RU-486 did not significantly attenuate the fall in IGF-I content in skeletal muscle, heart, brain, or pituitary or the increase in IGF-I observed in kidney after IL-1β. Furthermore, pretreatment with RU-486 did not completely prevent the IL-1β-induced decrease in IGF-I mRNA in skeletal muscle. The concentration of both IGF-binding protein (BP)-1 and BP-2 was increased in plasma, liver, and muscle in response to IL-1β, and these changes were also not prevented by RU-486. These results indicate that the inflammatory cytokine IL-1β is capable of influencing multiple components of the IGF system. Whereas the enhanced endogenous production of glucocorticoids appears to mediate the IL-1β-induced decrease in IGF-I synthesis in liver, the changes in IGF-I content observed in other tissues and the increase in IGFBP-1 and IGFBP-2 appear to be largely glucocorticoid independent.

UR - http://www.scopus.com/inward/record.url?scp=0030004837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030004837&partnerID=8YFLogxK

M3 - Article

VL - 270

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 3 39-3

ER -